journal
MENU ▼
Read by QxMD icon Read
search

Oncologist

journal
https://www.readbyqxmd.com/read/30425180/acgh-analysis-of-predictive-biomarkers-for-response-to-bevacizumab-plus-oxaliplatin-or-irinotecan-based-chemotherapy-in-patients-with-metastatic-colorectal-cancer
#1
Yoshihiko Fujita, Masataka Taguri, Kentaro Yamazaki, Junji Tsurutani, Kazuko Sakai, Takahiro Tsushima, Michitaka Nagase, Hiroshi Tamagawa, Shinya Ueda, Takao Tamura, Yasushi Tsuji, Kohei Murata, Koichi Taira, Tadamichi Denda, Toshikazu Moriwaki, Sadao Funai, Takako Eguchi Nakajima, Kei Muro, Akihito Tsuji, Motoki Yoshida, Koichi Suyama, Takuya Kurimoto, Naotoshi Sugimoto, Eishi Baba, Nobuhiko Seki, Mikio Sato, Takaya Shimura, Narikazu Boku, Ichinosuke Hyodo, Takeharu Yamanaka, Kazuto Nishio
BACKGROUND: The randomized phase III study (WJOG4407G) showed equivalent efficacy between FOLFOX and FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (mCRC). We studied whole genome copy number profiles using array-based comparative genomic hybridization (aCGH) analysis of tumor tissue samples obtained in this study. The aim of this study was to identify gene copy number alterations that could aid in selecting either FOLFOX or FOLFIRI in combination with bevacizumab for patients with mCRC...
November 13, 2018: Oncologist
https://www.readbyqxmd.com/read/30425179/how-does-a-supervised-exercise-program-improve-quality-of-life-in-patients-with-cancer-a-concept-mapping-study-examining-patients-perspectives
#2
Maike G Sweegers, Laurien M Buffart, Wouke M van Veldhuizen, Edwin Geleijn, Henk M W Verheul, Johannes Brug, Mai J M Chinapaw, Teatske M Altenburg
BACKGROUND: Previous systematic reviews and meta-analyses demonstrated beneficial effects of exercise during or following cancer treatment on quality of life (QoL). Aiming to understand how exercise contributes to a patient's QoL, we examined patients' perspectives via a process called concept mapping. This unique method provides structure and objectivity to rich qualitative data. METHODS: Patients with cancer who were participating in an exercise program were invited to enroll...
November 13, 2018: Oncologist
https://www.readbyqxmd.com/read/30413669/first-in-human-phase-i-study-of-mbc-11-a-novel-bone-targeted-cytarabine-etidronate-conjugate-in-patients-with-cancer-induced-bone-disease
#3
Shawn Patrick Zinnen, Alexander Karpeisky, Daniel D Von Hoff, Larisa Plekhova, Alexander Alexandrov
LESSONS LEARNED: Results are consistent with MBC-11 targeting and treating cancer-induced bone lesions by concentrating cytarabine and etidronate at the site of disease.MBC-11 was well tolerated, with an maximum tolerated dose of 5 mg/kg per day and myelosuppression as the principal toxicity.Treatment significantly reduced cancer cell activity in over half of bone lesions detected at baseline.MBC-11 pharmacokinetic and pharmacodynamic parameters are consistent with the novel drug design goals, and encouraging results warrant further clinical development...
November 9, 2018: Oncologist
https://www.readbyqxmd.com/read/30413668/characterization-of-comorbidities-limiting-the-recruitment-of-patients-in-early-phase-clinical-trials
#4
Narjust Duma, Sejal M Kothadia, Tariq U Azam, Siddhartha Yadav, Jonas Paludo, Jesus Vera Aguilera, Miguel Gonzalez Velez, Thorvardur Ragnar Halfdanarson, Julian R Molina, Joleen M Hubbard, Ronald S Go, Aaron S Mansfield, Alex A Adjei
BACKGROUND: Early phase clinical trials evaluate the safety and efficacy of new treatments. The exclusion/inclusion criteria in these trials are usually rigorous and may exclude many patients seen in clinical practice. Our objective was to study the comorbidities limiting the participation of patients with breast, colorectal, or lung cancer in clinical trials. MATERIALS AND METHODS: We queried ClinicalTrials.gov on December 31, 2016. We reviewed the eligibility criteria of 1,103 trials...
November 9, 2018: Oncologist
https://www.readbyqxmd.com/read/30413667/eribulin-mesylate-as-third-or-subsequent-line-chemotherapy-for-elderly-patients-with-locally-recurrent-or-metastatic-breast-cancer-a-multicentric-observational-study-of-gioger-italian-group-of-geriatric-oncology-eribe
#5
Silvana Leo, Ermenegildo Arnoldi, Lazzaro Repetto, Zaira Coccorullo, Saverio Cinieri, Mina Fedele, Marina Cazzaniga, Vito Lorusso, Agnese Latorre, Giovanna Campanella, Mariangela Ciccarese, Caterina Accettura, Salvatore Pisconti, Antonio Rinaldi, Cosimo Brunetti, Mimma Raffaele, Luigi Coltelli, Salvatore Spazzapan, Lucia Fratino, Luciana Petrucelli, Laura Biganzoli
BACKGROUND: Metastatic breast cancer (MBC) is highly prevalent in middle-aged or elderly patients. Eribulin is a nontaxane microtubule inhibitor, approved for the treatment of pretreated MBC. This multicentric study (sponsored by GIOGer, Italian Group for Geriatric Oncology) was designed to assess the efficacy and tolerability of eribulin, according to parameters usually used in geriatric oncology. SUBJECTS, MATERIALS, AND METHODS: An observational study was conducted on 50 consecutive elderly patients with MBC...
November 9, 2018: Oncologist
https://www.readbyqxmd.com/read/30413666/capecitabine-and-temozolomide-as-a-promising-therapy-for-advanced-thymic-atypical-carcinoid
#6
Xin Wang, Yuanliang Li, Jianghui Duan, Yingying Chen, Bing Yuan, Zhirong Qi, Huangying Tan
BACKGROUND: Thymic atypical carcinoid (TAC) is a rare thymic neuroendocrine tumor that originates in the neuroendocrine system and lacks a standardized treatment. The combination of capecitabine (CAP) and temozolomide (TEM) is associated with an extremely high and long-lasting response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is little evidence showing that the CAPTEM regimen is effective for TAC. For patients with unresectable or metastatic atypical carcinoid of the thymus, few treatment options are available, and the treatment efficacy is not satisfactory...
November 9, 2018: Oncologist
https://www.readbyqxmd.com/read/30413665/immune-checkpoint-inhibitors-and-the-risk-of-allograft-rejection-a-comprehensive-analysis-on-an-emerging-issue
#7
Luis E Aguirre, Maria E Guzman, Gilberto Lopes, Judith Hurley
BACKGROUND: It is well known that the state of immune tolerance induced by broad immunosuppression to prevent allograft rejection leads to an increased risk of the development of cancer. One of the most promising new areas of cancer treatment has been the development of immune checkpoint inhibitors that target the cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1/programmed death-ligand 1 (PD-L1) pathways. As a logical consequence, growing interest in these agents translated into their implementation in patients with transplant-related malignancies...
November 9, 2018: Oncologist
https://www.readbyqxmd.com/read/30413664/protecting-patient-privacy-in-narratives-the-lifespan-brown-checklist-for-appropriate-use-of-patient-narratives
#8
William Rafelson, Jane Bruno, Don S Dizon
No abstract text is available yet for this article.
November 9, 2018: Oncologist
https://www.readbyqxmd.com/read/30413663/smad4-mutation-in-small-cell-transformation-of-epidermal-growth-factor-receptor-mutated-lung-adenocarcinoma
#9
Nicky D'Haene, Marie Le Mercier, Isabelle Salmon, Zita Mekinda, Myriam Remmelink, Thierry Berghmans
The large screening of exons 18 to 21 of the epidermal growth factor receptor (EGFR) gene may lead to the discovery of rare, atypical molecular alterations for which the sensitivity to tyrosine kinase inhibitors (TKIs) remains uncertain. We are reporting a rare exon 18 EGFR mutation (p.E709_710 > D) that confers sensitivity to second-generation EGFR TKI (afatinib), lasting for 1 year. Tumor progression biopsy showed small cell lung cancer transformation, associated with a SMAD4 mutation. KEY POINTS: A rare exon 18 epidermal growth factor receptor mutation with sensitivity to afatinib is reported...
November 9, 2018: Oncologist
https://www.readbyqxmd.com/read/30413662/-as-long-as-you-ask-a-qualitative-study-of-biobanking-consent-oncology-patients-and-health-care-professionals-attitudes-motivations-and-experiences-the-b-ppae-study
#10
Sonia Yip, Jennifer Fleming, Heather L Shepherd, Adam Walczak, Jonathan Clark, Phyllis Butow
INTRODUCTION: Consent to biobanking remains controversial, with little empirical data to guide policy and practice. This study aimed to explore the attitudes, motivations, and concerns of both oncology patients and health care professionals (HCPs) regarding biobanking. MATERIALS AND METHODS: Qualitative interviews were conducted with oncology patients and HCPs purposively selected from five Australian hospitals. Patients were invited to give biobanking consent as part of a clinical trial and/or for future research were eligible...
November 9, 2018: Oncologist
https://www.readbyqxmd.com/read/30409793/relevance-of-reference-centers-in-sarcoma-care-and-quality-item-evaluation-results-from-the-prospective-registry-of-the-spanish-group-for-research-in-sarcoma-geis
#11
Javier Martin-Broto, Nadia Hindi, Josefina Cruz, Javier Martinez-Trufero, Claudia Valverde, Luis M De Sande, Angeles Sala, Lorena Bellido, Ana De Juan, Jordi Rubió-Casadevall, Roberto Diaz-Beveridge, Ricardo Cubedo, Oscar Tendero, Diego Salinas, Isidro Gracia, Rafael Ramos, Silvia Baguè, Antonio Gutierrez, José Duran-Moreno, Antonio Lopez-Pousa
BACKGROUND: Reference centers (RCs) are a key point for improving the survival of patients with soft-tissue sarcomas (STS). The aim of this study was to evaluate selected items in the management of patients with STS, comparing results between RC and local hospitals (LHs). MATERIALS AND METHODS: Diagnostic and therapeutic data from patients diagnosed between January 2004 and December 2011 were collected. Correlation with outcome was performed. RESULTS: A total of 622 sarcomas were analyzed, with a median follow-up of 40 months...
November 8, 2018: Oncologist
https://www.readbyqxmd.com/read/30409792/age-and-the-risk-of-paclitaxel-induced-neuropathy-in-women-with-early-stage-breast-cancer-alliance-a151411-results-from-1-881-patients-from-cancer-and-leukemia-group-b-calgb-40101
#12
Myra Barginear, Amylou C Dueck, Jacob B Allred, Craig Bunnell, Harvey J Cohen, Rachel A Freedman, Arti Hurria, Gretchen Kimmick, Jennifer G Le-Rademacher, Stuart Lichtman, Hyman B Muss, Lawrence N Shulman, M Sitiki Copur, David Biggs, Bhuvaneswari Ramaswamy, Jacqueline M Lafky, Aminah Jatoi
PURPOSE: A few previous studies report a direct relationship between older age and chemotherapy-induced neuropathy. This study further evaluated this adverse event's age-based risk. METHODS: CALGB 40101 investigated adjuvant paclitaxel (80 mg/m2 once per week or 175 mg/m2 every 2 weeks) in patients with breast cancer and served as a platform for the current study that investigated age-based differences in neuropathy. Grade 2 or worse neuropathy, as per Common Terminology Criteria for Adverse Events version 4, was the primary endpoint; patients were assessed at baseline, every 6 months for 2 years, and then annually for 15 years...
November 8, 2018: Oncologist
https://www.readbyqxmd.com/read/30389744/takotsubo-cardiomyopathy-during-anti-her2-therapy-for-metastatic-breast-cancer
#13
Caitlin Lees, Payam Yazdan-Ashoori, Katarzyna J Jerzak, Sonal Gandhi
Human epidermal growth factor receptor 2 (HER2)-targeted antibodies, including pertuzumab and trastuzumab, improve overall survival and progression-free survival among women with HER2-positive metastatic breast cancer, but grade ≥3 cardiotoxicity occurs in approximately 8% of cases. Here we report a case of Takotsubo cardiomyopathy associated with the use of dual anti-HER2 therapy in a 63-year-old woman who presented to the emergency department with an 8- to 10-hour history of progressive dyspnea after completing her third cycle of pertuzumab plus trastuzumab in addition to nab-paclitaxel chemotherapy...
November 2, 2018: Oncologist
https://www.readbyqxmd.com/read/30373905/genomic-profiling-of-parathyroid-carcinoma-reveals-genomic-alterations-suggesting-benefit-from-therapy
#14
Hyunseok Kang, Dean Pettinga, Adrian D Schubert, Paul W Ladenson, Douglas W Ball, Jon H Chung, Alexa B Schrock, Russell Madison, Garrett M Frampton, Phil J Stephens, Jeffrey S Ross, Vincent A Miller, Siraj M Ali
BACKGROUND: Parathyroid carcinoma (PC) is a rare endocrine malignancy that can cause life-threatening hypercalcemia. We queried whether comprehensive genomic profiling (CGP) of PC might identify genomic alterations (GAs), which would suggest benefit from rationally matched therapeutics. METHODS: We performed hybrid-capture-based CGP to identify GAs and tumor mutational burden (TMB) in tumors from patients with this malignancy. RESULTS: There were 85 total GAs in 16 cases (5...
October 29, 2018: Oncologist
https://www.readbyqxmd.com/read/30373904/enrichment-of-her2-amplification-in-brain-metastases-from-primary-gastrointestinal-malignancies
#15
Devarati Mitra, Jeffrey W Clark, Helen A Shih, Kevin S Oh, Priscilla K Brastianos, Jennifer Y Wo, Matthew R Strickland, William T Curry, Aparna R Parikh, Ryan B Corcoran, David P Ryan, A John Iafrate, Darrell R Borger, Jochen K Lennerz, Theodore S Hong
BACKGROUND: In nongastric gastrointestinal (GI) cancers, HER2-positive (HER2+) disease is not common. In breast cancer, HER2 status is associated with increased risk of brain metastases and response to HER2-targeted therapy. The purpose of this project was to compare HER2 status in GI cancer brain metastases versus matched prior sites of disease in order to determine if HER2+ disease is more common intracranially. MATERIALS AND METHODS: We identified 28 patients with GI cancer who had craniotomy for brain metastases between 1999 and 2017 with intracranial metastatic tissue available at Massachusetts General Hospital...
October 29, 2018: Oncologist
https://www.readbyqxmd.com/read/30361422/phase-ii-trial-of-5-fluorouracil-docetaxel-and-nedaplatin-udon-combination-therapy-for-recurrent-or-metastatic-esophageal-cancer
#16
Hiroto Ueda, Hisato Kawakami, Yoshikane Nonagase, Naoki Takegawa, Tatsuya Okuno, Takayuki Takahama, Masayuki Takeda, Yasutaka Chiba, Takao Tamura, Kazuhiko Nakagawa
LESSONS LEARNED: The 5-fluorouracil, docetaxel, and nedaplatin (UDON) regimen was well tolerated and showed promising antitumor activity in terms of both objective response rate and survival for patients with advanced or recurrent esophageal squamous cell carcinoma in the first-line setting.UDON may be an optimal treatment option for patients with advanced esophageal cancer who are unfit for docetaxel, cisplatin, and 5-fluorouracil regimens.The high response rate as well as the rapid and marked tumor shrinkage associated with UDON suggest that further evaluation of this regimen in the neoadjuvant setting is warranted...
October 25, 2018: Oncologist
https://www.readbyqxmd.com/read/30355776/symptom-expression-in-patients-with-advanced-cancer-admitted-to-an-acute-supportive-palliative-care-unit-with-and-without-delirium
#17
Sebastiano Mercadante, Claudio Adile, Patrizia Ferrera, Andrea Cortegiani, Alessandra Casuccio
AIM: The aim of this study was to investigate the relationship between delirium and symptom expression in patients with advanced cancer admitted to an acute supportive/palliative care unit (ASPCU). METHODS: A consecutive sample of patients with advanced cancer who were admitted to an ASPCU was prospectively assessed for a period of 10 months. The Edmonton Symptom Assessment Scale (ESAS) and the MDAS (Memorial Delirium Assessment Scale) were measured at admission (T0) and after 7 days of palliative care (T7)...
October 24, 2018: Oncologist
https://www.readbyqxmd.com/read/30355775/effect-of-lanreotide-depot-autogel-on-urinary-5-hydroxyindoleacetic-acid-and-plasma-chromogranin-a-biomarkers-in-nonfunctional-metastatic-enteropancreatic-neuroendocrine-tumors
#18
Marianne E Pavel, Alexandria T Phan, Edward M Wolin, Beloo Mirakhur, Nilani Liyanage, Susan Pitman Lowenthal, George A Fisher, Aaron I Vinik
BACKGROUND: Urinary 5-hydroxyindoleacetic acid (5-HIAA) is an established biomarker in neuroendocrine tumors and carcinoid syndrome; however, its role in nonfunctional neuroendocrine tumors is not defined. We present post hoc data on urinary 5-HIAA and plasma chromogranin A (CgA) from the CLARINET study. METHODS: Patients with well- or moderately differentiated, nonfunctioning, locally advanced or metastatic enteropancreatic neuroendocrine tumors were randomized to deep subcutaneous lanreotide depot/autogel 120 mg or placebo once every 28 days for 96 weeks...
October 24, 2018: Oncologist
https://www.readbyqxmd.com/read/30355774/cases-from-the-irae-tumor-board-a-multidisciplinary-approach-to-a-patient-treated-with-immune-checkpoint-blockade-who-presented-with-a-new-rash
#19
Pradnya D Patil, Anthony P Fernandez, Vamsidhar Velcheti, Ahmad Tarhini, Pauline Funchain, Brian Rini, Mohamad Khasawneh, Nathan A Pennell
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigms for a broad spectrum of malignancies. Because immune checkpoint inhibitors rely on immune reactivation to eliminate cancer cells, they can also lead to the loss of immune tolerance and result in a wide range of phenomena called immune-related adverse events (irAEs). At our institution, the management of irAEs is based on multidisciplinary input obtained at an irAE tumor board that facilitates expedited opinions from various specialties and allows for a more uniform approach to these patients...
October 24, 2018: Oncologist
https://www.readbyqxmd.com/read/30355773/conflicts-of-interest-baselga-and-clinical-trialists
#20
EDITORIAL
Oliver Sartor
No abstract text is available yet for this article.
October 24, 2018: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"